EN | TR
E-ISSN: 3061-9947
The Impact of non-COVID-19 Infections to COVID-19 Disease in Hematological and Solid Organ Malignancies
PDF
Cite
Share
Request
Original Article
VOLUME: 55 ISSUE: 3
P: 261-269
2022

The Impact of non-COVID-19 Infections to COVID-19 Disease in Hematological and Solid Organ Malignancies

Acta Haematol Oncol Turc 2022;55(3):261-269
DOI: 10.5505/aot.2022.03206
Atakan Tekinalp 1
Hilal Akay Çizmecioğlu 2
Mevlüt Hakan Göktepe 2
Sinan Demircioğlu 1
Ali Kürşat Tuna 2
Melek Karakurt Eryılmaz 3
1. Necmettin Erbakan Univercity Meram Faculty Of Medicine, Division Of Internal Medicine, Department Of Hematology
2. Necmettin Erbakan Univercity Meram Faculty Of Medicine, Division Of Internal Medicine
3. Necmettin Erbakan Univercity Meram Faculty Of Medicine, Division Of Internal Medicine, Department Of Oncology
4.
No information available.
No information available
Received Date: 2022-04-21T17:47:51
Accepted Date: 2022-11-30T19:39:39
PDF
Cite
Share
Request

Abstract

INTRODUCTION

The aim of this study is to evaluate the clinical differences of COVID-19 infection in hematological and solid organ malignancy patients.

METHODS

In the study, patients who have followed up in the Necmettin Erbakan University Meram Medical Faculty Clinic of COVID-19 with a diagnosis of malignancy between 01 September 2020 and 01 January 2021 were compared in terms of epidemiological and clinical characteristics.

RESULTS

The study included 134 patients. Hospitalization day, intensive care need, convalescent plasma need, sedimentation and ferritin levels of patients diagnosed with hematological malignancies were significantly higher (p: 0.001, 0.008, 0.001, 0.001, <0.001 respectively), and the neutrophil, lymphocyte, platelet, and neutrophil-lymphocyte ratio was found to be low, according to the findings of the study. The cure rate of COVID infection was significantly lower with additionally infection in hematological malignancies (OR: 3.1, 95%; CI: 1.4-6.9; p: 0.004). In multivariate analysis, it was determined that an presence of non-COVID-19 infection increased the risk of death 2.8 times (95% CI; 1.3-6.5, p: 0.010).

DISCUSSION AND CONCLUSION

Patients with hematological malignancy have experienced a more severe clinical course of COVID-19 and higher mortality than those with solid tumors. The use of a model in the COVID-19 pandemic that summarizes these non-COVID-19 infections, hematological parameters, age, and comorbidities can help in the method of malignant patients with high mortality risk.